SWOG clinical trial number
SWOG-8923
Neo-FAC for Poor Prognosis Stage IV Breast Cancer, A Phase II Pilot Study
Closed
Phase
Accrual
60%
Published
Abbreviated Title
Neo-FAC for Poor Prognosis St.IV Breast Cancer
Activated
02/15/1990
Closed
06/01/1992
Research committees
Breast Cancer
Treatment
Cyclophosphamide
5-Fluorouracil
Doxorubicin
Publication Information Expand/Collapse
1999
"Neo-FAC" (5-fluorouracil, doxorubicin and cyclophosphamide) for poor prognosis stage IV breast cancer: A Southwest Oncology Group Phase II study.
Other Clinical Trials
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
3%
Open
Phase
SWOG Clinical Trial Number
S2212
TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase